?> Contact us Follow Us
Biosimilars Forum
  • About Us
    • Members
    • Executive Director
  • Why Biosimilars
    • The Issue
    • Our Solutions
  • Biosimilars 101
    • Foundations
    • Core Principles
    • FDA Regulatory Tenets
    • Biosimilars FAQs
    • Future Evolution of Biosimilar Development
    • Approved Biosimilars
  • Advocacy
    • Our Action
    • Tools
  • News
  • Resources
  • Get Involved
    • Partners

signalgroup

Get more out of your business.
Reach it with Microsoft Dynamics 365 Business Central.
News
July 25, 2023 signalgroup
Biosimilars Forum Applauds Boehringer Ingelheim for Launch of Cyltezo®
News
July 10, 2023 signalgroup
Biosimilars Forum Congratulates Fresenius Kabi for Launch of IDACIO®
News
July 6, 2023 signalgroup
Biosimilars Forum Applauds Sandoz for Launch of Hyrimoz®
News
July 6, 2023 signalgroup
Biosimilars Forum Applauds Organon and Samsung Bioepis for Launch of HADLIMA™
News
July 5, 2023 signalgroup
Biosimilars Forum Applauds Coherus for Launch of YUSIMRY™
News
June 30, 2023 signalgroup
Delivering on a Watershed Moment for Biosimilars and Patients
News
April 10, 2023 signalgroup
Biosimilars Key to Lowering Healthcare and Prescription Drug Costs, According to Employers
News
March 30, 2023 signalgroup
Biosimilars Forum Applauds the U.S. Senate Finance Committee for Holding PBMs Accountable for Prioritizing Profits over Patients
News
March 3, 2023 signalgroup
Biosimilars Forum Applauds Congressman Hudson for Supporting Biosimilars Through Shared Savings Legislation
News
January 31, 2023 signalgroup
The Biosimilars Forum Calls on Decisionmakers to Deliver on Humira Biosimilars
  • Prev page
  • 01
  • 02
  • 03
  • 04
  • 05
  • Next page

  • Biosimilars 101
  • Biosimilars FAQs
  • Advocacy
  • Stay Connected
Biosimilars Forum
© 2025 Biosimilars Forum. All rights reserved.
  • Terms of Use
  • |
  • Privacy Policy
  • |
  • Contact Us